Close
Log-In
|
Home
|
E-mail Alerts
|
My Headlines
|
Portfolio
Home
Menu
JOIN
SI Premium
Ratings
Mergers
Earnings
Dividends
IPOs
Hedge Funds
Premium Letters
Send a Tip
API/Data
JOIN
SI Premium
Full Feed View
Headline View
SI Premium Squawk Box
Alerts
Custom Headlines
Upgrade Your Current Account
API
Calendars
Co. NDR/Event Calendar
Dividend Calendar
Earnings Calendar
Event Driven
FDA Calendar
Investor Conferences
IPO Calendar
Merger Arb
Ratings Calendar
Stock Split Calendar
Ratings
Analyst Comments
Hot Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Credit Ratings
Downgrade News
Hot Downgrades
New Coverage News
Hot New Coverage
Upgrade News
Hot Upgrades
More...
Mergers
Merger News
Hot M&A News
Private Equity
Rumors
SPAC News
Spinoffs
Merger Arbitrage
Event Driven
2021 Top M&A Deals
Top 50 Takeover Targets
More...
Earnings
Earnings Calendar
Earnings News
Hot Earnings
Guidance
Hot Guidance
Conference Calls
Earnings History Search
More...
Dividends
Dividend Calendar
Dividend News
Hot Dividends
Dividend Hike
Special Dividends
Stock Buybacks
Hot Stock Buybacks
Stock Splits
More...
IPOs
IPO News
Hot IPOs
Equity Offerings
Recent IPOs
Upcoming IPOs
2021 Top IPOs
More...
Hedge Funds
13D
13F
13G
Hedge Funds News
Hot Insider Trades
Insider Trades
More...
Premium Letters
Pulse Picks
Stealth Growth Insider
Send a Tip
API/Data
QUICK LINKS :
Goldman Sachs Conviction Buy List
Warren Buffett News
Elliott Management News
Follow @Street_Insider
Mirna Therapeutics (MIRN) Halts Clinical Study of MRX34 Following Severe Adverse Events
Article
Related Press Releases (
1
)
Related Articles (
2
)
Stock Quotes (1)
FREE Breaking News Alerts from StreetInsider.com!
E-mail Address
StreetInsider.com Top Tickers, 4/26/2024
1.
META
2.
GOOGL
3.
MSFT
4.
CMG
5.
SPY
6.
LRCX
7.
INTC
8.
SNAP
9.
IBM
10.
BA
Top News
Most Read
Special Reports
Stocks face worst month since September, yen swings after BoJ
Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
Oil prices on track to snap two-week losing streak
Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
Union Pacific beats profit estimates on stronger pricing, resumes share buyback
IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
After-hours movers: Meta, Ford, IBM, ServiceNow and more
Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Go back to Mirna Therapeutics (MIRN) Halts Clinical Study of MRX34 Following Severe Adverse Events
